Ziccums affärsidé är att utveckla nya beredningar av biologiska läkemedel genom bolagets patenterade teknologi LaminarPace, som utvecklar torra beredningsformer av produkter som i nuläget enbart finns i vätskeform.
Bransch: Sjukvård Marknad: First North Stockholm Tickerkod: ZICC Certified Adviser: Erik Penser Bank
I grafen visas aktiekursutveckling och omsättning för valt bolag. Informationen är fördröjd med 15 min.
Omsättning
Aktuell Kurs
Utvecklingen i dag
Analyser | 27 Sep 2022 | Ziccum
Ziccum reopens application for CEPI…
Ziccum AB (publ) (‘Ziccum’) today announces that is has reopened its application process for CEPI’s Call for Proposals (CfP) from companies developing innovative technologies to improve vaccine thermostability. Ziccum will…
Ziccum AB (publ) (‘Ziccum’) has today received readout results from the latest stage of an evaluation agreement study carried out with a leading pharmaceutical corporation (previously communicated on June 3,…
Following their agreed collaboration, Ziccum AB and the team from the ICP Institute of Computational Physics at the Zurich University of Applied Sciences’s School of Engineering (ZHAW) have now submitted…
Ziccum AB will be intensifying its partnering and networking dialogues at a series of leading pharma industry events throughout Europe this year. CEO Ann Gidner: “As we strengthen our connections…
INTERIM REPORT Q2 2022: 1 JANUARY – 30 JUNE 2022. To read the digital Report click here: https://reports-en.ziccum.com/interim-report-q2-2022/ Significant events during Q2 (April-June) Ziccum AB has significantly expanded its lab…
Ziccum AB has appointed a Scientific Director, as part of a major reorganisation aiming to facilitate and accelerate its new strategic focus on key projects and vaccine platforms. Ziccum Senior…
Ziccum AB, in partnership with the prestigious Zurich University of Applied Sciences, is applying for funding to Eurostars for a joint project developing the 3D modelling of LaminarPace, its unique…
Ziccum has chosen TEKCELEO, an innovative mechatronic manufacturer with advanced knowledge of nebulizers, for the development of its new nebulizer. The component is central to the advanced drying capabilities and…
In Ziccum’s recent major strategy renewal it sharpened its focus onto three key vaccine platforms and streamlined its R&D projects down to three key partnerships. The company is also pleased…
Lund, June 22, 2022 —Ziccum AB (publ) (‘Ziccum’) has completed the installation of a new cell lab, on schedule, as part of its strategy of intensive technology development. The new…
ca.penser.se använder cookies för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder cookies. Vad är cookies?
Kommande händelser